

Cytotoxic Sesquiterpenes from *Nardostachys chinensis*

Hideji ITOKAWA,* Koichi MASUYAMA, Hiroshi MORITA and Koichi TAKEYA

Department of Pharmacognosy, Tokyo College of Pharmacy, Horinouchi 1432-1, Hachioji, Tokyo 192-03, Japan.

Received November 6, 1992

Five cytostatic sesquiterpenes, desoxo-narchinol-A (**1**), nardosinone (**2**), debilon (**3**), nardosinonediol (**4**) and kanshone A (**5**), were isolated from the roots and rhizomes of *Nardostachys chinensis* (Valerianaceae). The steric structure of **1** was determined by nuclear Overhauser effects (NOEs) and the exciton chirality method. All five showed cytotoxic activity against P-388 cells and the structure–activity relationship of **1** was also discussed.

Keywords desoxo-narchinol-A; cytotoxic activity; *Nardostachys chinensis*; Valerianaceae; sesquiterpene

Introduction

The roots and rhizomes of *Nardostachys chinensis* have been used for stomach complaints and sedative purposes in Oriental medicine. During our survey of novel cytotoxic antitumour compounds from medicinal plants,¹⁾ we found that the methanolic extract of *N. chinensis* showed cytotoxic activity (IC₅₀ 21 µg/ml) against P-388 cells.

Chromatographic purification of the components exhibiting cytotoxicity led us to isolate some sesquiterpenes from *N. chinensis*. In this paper, the structural elucidation of these cytotoxic principles and their structure–activity relationships are reported.

Results and Discussion

The methanol extract of *N. chinensis* was successively partitioned between *n*-hexane, ethyl acetate, *n*-butanol and water. The cytotoxic activity of *N. chinensis* was concentrated in the ethyl acetate soluble fraction, which showed a cytotoxic activity of IC₅₀ 12.5 µg/ml against P-388 cells. Repeated chromatographic purification, conducted in conjunction with bio-assay against P-388 cells, led to the isolation of five sesquiterpenes, desoxo-narchinol-A (**1**), nardosinone (**2**), debilon (**3**), nardosinonediol (**4**) and kanshone A (**5**).

Compound **1** was obtained as colourless needles, mp 105–109 °C, [α]_D –186.0° (*c*=0.21, CHCl₃) with the molecular formula, C₁₂H₁₆O₂ (192.1128), suggesting a trinor-sesquiterpene. In the ¹H-nuclear magnetic resonance (NMR) spectrum (CDCl₃), two methyl groups at δ 0.95 and 0.96, an equally coupled (*J*=10.0 Hz) olefinic protons at δ 6.14 and 7.04 indicated the presence of an α , β -unsaturated carbonyl group and an olefinic proton at δ 7.04 indicated a β -proton on an α , β -unsaturated carbonyl group. Furthermore, a proton at δ 4.06 attached to the carbon bearing a hydroxyl group was coupled to the β -proton at δ 7.04. Infrared (IR) absorptions at 3650 and 1680 cm⁻¹ revealed the presence of hydroxyl and conjugated carbonyl groups, respectively.

From these data, desoxo-narchinol-A derived from nardosinone²⁾ was deduced to have the structure **1**. ¹³C-NMR data also corroborated this structure. However, as the configuration at C-6 was not clear, it was determined by NOEs and the allylic alcohol exciton chirality method³⁾ as follows. In the ¹H-NMR spectrum (pyridine-*d*₅), irradiation of a singlet methyl signal at δ 0.94 increased an integrated intensity of H-6 at δ 4.21. Then, the benzoate derivative (**6**) of **1** showed a negative Cotton effect at 241 nm. Therefore, the configuration at C-6 was determined to be *S*. This is the first example isolated from natural sources.

The structures of compounds **2**–**5** were found to be identical to nardosinone (**2**),⁴⁾ debilon (**3**),⁵⁾ nardosinonediol (**4**)⁶⁾ and kanshone A (**5**),⁴⁾ respectively, by comparing spectroscopic data.

All of the compounds obtained showed cytotoxic activities against P-388 cells (Table I). Compound **1**, which showed the most potent activity, was converted to the quinone-type compound **7** by oxidation with pyridinium chlorochromate (PCC) and to several esters; benzoate (**6**), acetate (**8**), propionate (**9**) and *n*-butyrate (**10**). As is clearly shown in Table I, the quinone-type compound **7** showed the most potent activity and increasing the ester chain length was considered to lead to increased cytotoxicity.

Experimental

All melting points were recorded on a Yanagimoto MP-3 micromelting




Fig. 1. Molecular Structures of Compounds **1**–**10**

TABLE I. Cytotoxic Activities of Compounds **1**–**10** against P388 Cells

Compd.	IC ₅₀ (µg/ml)	Compd.	IC ₅₀ (µg/ml)
1	2.2	6	0.14
2	18.5	7	0.11
3	13.0	8	0.60
4	13.0	9	0.48
5	7.0	10	0.32

point apparatus and are uncorrected. The spectral data were obtained on the following instruments: optical rotation on a JASCO DIP-4, IR spectra on a JASCO A-302, ultraviolet spectra (UV) on a Hitachi 557, NMR spectra on a Bruker AM400 and mass spectra (MS) on a Hitachi M-80. Medium-pressure liquid chromatography (MPLC) was carried out on a CIG column (Kusano Scientific Co., Tokyo) packed with 10 μ m silica gel as the stationary phase. Reversed-phase high-pressure liquid chromatography (HPLC) was carried out on an Inertsil PREP-ODS column packed with 10 μ m octadecyl silica (ODS).

Bioassay of Cytotoxic Activity against P388 Cells See previous paper.⁷⁾

Extraction and Isolation The roots and rhizomes of *N. chinensis* (1.0 kg, purchased from Uchidawakanyaku, Tokyo, 1991) were extracted three times with hot methanol and concentrated to give a methanolic extract (204 g). This extract was successively partitioned between *n*-hexane, ethyl acetate, *n*-butanol and water. The cytotoxic activity was concentrated in the ethyl acetate soluble fraction (71 g), which was subjected to silica gel column chromatography using a methylene chloride–methanol gradient system. Further chromatographic purification of the active fraction by silica gel MPLC (*n*-hexane–ethyl acetate solvent system) and ODS-HPLC (methanol–water and acetonitrile–water solvent system) led to the isolation of desoxo-narchinol-A (**1**: 337 mg), nardosinone (**2**: 265 mg), debilon (**3**: 85 mg), nardosinonediol (**4**: 1225 mg) and kanshone A (**5**: 485 mg).

Desoxo-narchinol-A (1): Colorless needles, mp 105–109°C, $[\alpha]_D^{20}$ –186° ($c=0.21$, CHCl₃). High Resolution-MS: Calcd for C₁₂H₁₆O₂: 192.1150. Found: 192.1128 (M⁺). MS m/z (%): 192 (M⁺, 52), 163 (100), 148 (80), 91 (85), 77 (75). ¹H-NMR (CDCl₃) δ ppm: 0.95 (3H, s, H-14), 0.96 (3H, d, $J=6.8$ Hz, H-15), 4.06 (1H, d, $J=6.0$ Hz, H-6), 6.14 (1H, d, $J=10.0$ Hz, H-8), 7.04 (2H, m, H-1, H-7). ¹H-NMR (pyridine-*d*₅) δ ppm: 0.94 (3H, s, H-14), 0.97 (3H, d, $J=6.8$ Hz, H-15), 4.21 (1H, d, $J=6.0$ Hz, H-6), 6.32 (1H, d, $J=10.0$ Hz, H-8), 7.10 (1H, dd, $J=4.9$, 2.9 Hz, H-1), 7.19 (1H, dd, $J=10.0$, 6.0 Hz, H-7). ¹³C-NMR (CDCl₃) δ ppm: 14.9 (C-15), 19.7 (C-14), 25.6 (C-3), 26.3 (C-2), 30.9 (C-4), 42.5 (C-5), 68.4 (C-6), 130.5 (C-1), 138.5 (C-10), 140.6 (C-7), 146.4 (C-8), 187.2 (C-9). IR (CHCl₃) cm⁻¹: 3650, 1680, 1620. UV λ_{max}^{MeOH} nm (log ϵ): 232 (5.21).

Nardosinone (2): $[\alpha]_D^{20} +27.5^\circ$ ($c=0.20$, CHCl₃). MS m/z (%): 250 (M⁺, 6), 192 (4), 93 (100), 79 (90). ¹H-NMR (CDCl₃) δ ppm: 1.03 (3H, d, $J=6.7$ Hz, H-15), 1.14 (3H, s, H-14), 1.18, 1.38 (each 3H, s, H-12, H-13), 2.65 (1H, dd, $J=18.8$, 1.9 Hz, H-8a), 2.89 (1H, dd, $J=18.8$, 7.3 Hz, H-8b), 2.93 (1H, d, $J=9.3$ Hz, H-6), 4.91 (1H, ddd, $J=9.3$, 7.3, 1.9 Hz, H-7), 7.05 (1H, dd, $J=5.1$, 2.7 Hz, H-1). ¹³C-NMR (CDCl₃) δ ppm: 16.1 (C-15), 22.1 (C-12), 23.8 (C-13), 25.8 (C-2, C-3), 26.9 (C-14), 33.0 (C-4), 38.5 (C-5), 39.9 (C-8), 59.7 (C-6), 78.0 (C-7), 85.0 (C-11), 137.6 (C-1), 140.1 (C-10), 196.4 (C-9). IR (CHCl₃) cm⁻¹: 2950, 1700, 1620. UV λ_{max}^{MeOH} nm (log ϵ): 248 (3.89).

Debilon (3): Colorless needles, mp 136°C, $[\alpha]_D^{20} -5.8^\circ$ ($c=0.14$, MeOH). MS m/z (%): 234 (M⁺, 24), 216 (45), 192 (50), 104 (67), 105 (92), 91 (100), 77 (86). ¹H-NMR (CDCl₃) δ ppm: 0.76 (1H, d, $J=9.3$ Hz, H-6), 0.92, 1.08, 1.44 (each 3H, s, H-12, H-13, H-14), 1.07 (3H, d, $J=7.3$ Hz, H-15), 4.21 (1H, dd, $J=4.0$, 2.2 Hz, H-9), 5.80 (1H, s, H-1). ¹³C-NMR (CDCl₃) δ ppm: 15.0 (C-15), 16.4 (C-7), 17.5 (C-12), 19.1 (C-11), 23.9 (C-13), 28.0 (C-8), 29.2 (C-14), 31.9 (C-4), 37.1 (C-6), 37.4 (C-5), 42.8 (C-3), 72.6 (C-9), 126.4 (C-1), 170.4 (C-10), 200.0 (C-2). IR (CHCl₃) cm⁻¹: 3620, 3489, 1680, 1620. UV λ_{max}^{MeOH} nm (log ϵ): 231 (3.95).

Nardosinonediol (4): Colorless needles, mp 141–143°C, $[\alpha]_D^{20} -1.7^\circ$ ($c=0.95$, MeOH). ¹H-NMR (CDCl₃) δ ppm: 0.93 (3H, d, $J=6.6$ Hz, H-15), 0.97 (3H, s, H-14), 1.30, 1.49 (each 3H, s, H-12, H-13), 2.43 (1H, d, $J=3.8$ Hz, H-8), 2.86 (1H, d, $J=11.0$ Hz, H-8), 4.53 (1H, ddd, $J=11.0$, 7.5, 3.8 Hz, H-7), 6.78 (1H, dd, $J=5.2$, 2.7 Hz, H-1). ¹³C-NMR (CDCl₃)

δ ppm: 16.1 (C-15), 25.4 (C-3), 25.9 (C-14), 26.2 (C-2), 29.2 (C-13), 32.6 (C-4), 37.4 (C-12), 40.2 (C-5), 46.0 (C-8), 52.5 (C-6), 68.1 (C-7), 77.5 (C-11), 136.8 (C-1), 142.0 (C-10), 200.7 (C-9). UV λ_{max}^{MeOH} nm (log ϵ): 249 (3.68).

Kanshone A (5): Colorless oil, $[\alpha]_D^{20} -150.6^\circ$ ($c=0.24$, MeOH). ¹H-NMR (CDCl₃) δ ppm: 1.00 (3H, d, $J=6.5$ Hz, H-15), 1.06, 1.15, 1.24 (each 3H, s, H-14, H-12, H-13), 2.25 (1H, m, H-4), 2.64 (1H, m, H-6), 6.18 (1H, d, $J=10.0$ Hz, H-8), 6.95 (1H, dd, $J=10.3$, 6.8 Hz, H-7), 7.00 (1H, dd, $J=3.4$ Hz, H-1). ¹³C-NMR (CDCl₃) δ ppm: 16.7 (C-15), 23.8 (C-12), 24.5 (C-13), 26.0 (C-2, C-3), 32.3 (C-14), 33.2 (C-4), 42.0 (C-5), 54.4 (C-6), 76.2 (C-11), 129.1 (C-8), 137.1 (C-1), 141.5 (C-10), 150.7 (C-7), 187.7 (C-9). UV λ_{max}^{MeOH} nm (log ϵ): 249 (3.68).

Preparation of Benzoate (6), Acetate (8), Propionate (9) and Butyrate (10)

A solution of **1** (13 mg) and benzoic anhydride in pyridine (1 ml) was stirred overnight, then poured into water, and extracted with CH₂Cl₂. The product was purified by silica gel MPLC eluting with an *n*-hexane–ethyl acetate solvent system to give **6** (7.2 mg). Compounds **8**, **9** and **10** were prepared in the same way as indicated above by using acetic anhydride, propionic anhydride and butyric anhydride, respectively.

Compound 6: MS m/z (%): 296 (M⁺, 5), 105 (100), 77 (46). ¹H-NMR (CDCl₃) δ ppm: 0.91 (3H, d, $J=6.9$ Hz, H-15), 1.11 (3H, s, H-14), 5.49 (1H, d, $J=6.0$ Hz, H-6), 6.30 (1H, d, $J=10.0$ Hz, H-8), 7.10–7.14 (2H, m, H-1, H-7), 7.43 (2H, t, $J=7.5$ Hz), 7.56 (1H, t, $J=7.5$ Hz), 7.95 (2H, d, $J=7.5$ Hz). IR (CHCl₃) cm⁻¹: 3700, 1718, 1675, 1618, CD (MeOH): $\Delta\epsilon_{240} = -49.83$, $\Delta\epsilon_{220} = +12.46$.

Compound 8: MS m/z (%): 234 (M⁺, 5), 192 (38), 159 (49), 84 (100). ¹H-NMR (CDCl₃) δ ppm: 0.88 (3H, d, $J=6.9$ Hz), 1.02 (3H, s), 2.02 (3H, s), 5.22 (1H, d, $J=6.0$ Hz), 6.23 (1H, d, $J=10.0$ Hz), 6.97 (1H, dd, $J=10.0$, 6.0 Hz), 7.03 (1H, t, $J=4.0$ Hz).

Compound 9: CI-MS m/z (%): 249 (M⁺+1, 11), 175 (19), 84 (100). ¹H-NMR (CDCl₃) δ ppm: 0.88 (3H, d, $J=6.9$ Hz), 1.03 (3H, s), 1.11 (3H, t, $J=7.6$ Hz), 5.22 (1H, d, $J=6.0$ Hz), 6.23 (1H, d, $J=10.0$ Hz), 6.99 (1H, dd, $J=10.0$, 6.0 Hz), 7.03 (1H, t, $J=4.0$ Hz).

Compound 10: CI-MS m/z (%): 263 (M⁺+1, 6), 192 (28), 175 (60), 84 (100). ¹H-NMR (CDCl₃) δ ppm: 0.88 (3H, d, $J=6.9$ Hz), 0.94 (3H, t, $J=8.4$ Hz), 1.05 (3H, s), 5.22 (1H, d, $J=6.0$ Hz), 6.23 (1H, d, $J=10.0$ Hz), 6.99 (1H, dd, $J=10.0$, 6.0 Hz), 7.04 (1H, t, $J=3.6$ Hz).

Preparation of Compound 7 Compound **1** (20 mg) was stirred with PCC (30 mg) in CH₂Cl₂ (3 ml) for 6 h at room temperature. Dry ether was then added, the reaction mixture was filtered and the filtrate was subjected to silica gel MPLC eluting with an *n*-hexane–ethyl acetate (1 : 1) solvent system to give **7** (16 mg): MS m/z (%): 190 (M⁺, 34), 175 (24), 148 (32), 84 (100). ¹H-NMR (CDCl₃) δ ppm: 1.15 (3H, d, $J=6.6$ Hz), 1.30 (3H, s), 6.65 (1H, d, $J=10.3$ Hz), 6.71 (1H, d, $J=10.3$ Hz), 6.85 (1H, m).

References

- 1) H. Itokawa, E. Kishi, H. Morita and K. Takeya, *Chem. Pharm. Bull.*, **40**, 1053 (1992); H. Morita, T. Yamamiya, K. Takeya and H. Itokawa, *ibid.*, **40**, 1352 (1992).
- 2) G. Rucker and E. Dyck, *Phytochemistry*, **13**, 1907 (1974).
- 3) N. Harada and K. Nakanishi, *Acc. Chem. Res.*, **5**, 257 (1972).
- 4) A. Bagchi, Y. Oshima and H. Hikino, *Phytochemistry*, **27**, 1199 (1988).
- 5) J. Krepinsky, G. Jommi, Z. Samek and F. Sorm, *Collection Czechoslov. Chem. Commun.*, **35**, 745 (1970).
- 6) A. Bagchi, Y. Oshima and H. Hikino, *Phytochemistry*, **27**, 3667 (1988).
- 7) H. Itokawa, N. Totsuka, H. Morita, K. Takeya, Y. Iitaka, E. P. Schenkel and M. Motidome, *Chem. Pharm. Bull.*, **38**, 3384 (1990).